Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid

Armin Mooranian; Nassim Zamani; Momir Mikov; Svetlana Goločorbin-Kon; Goran Stojanovic; Frank Arfuso; Hani Al-Salami

doi:10.4155/tde-2018-0036

Eudragit^®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid

Ther Deliv. 2018 Nov;9(11):811-821. doi: 10.4155/tde-2018-0036.

Authors

Armin Mooranian¹, Nassim Zamani¹, Momir Mikov², Svetlana Goločorbin-Kon³, Goran Stojanovic⁴, Frank Arfuso⁵, Hani Al-Salami¹

Affiliations

¹ Biotechnology & Drug Development Research Laboratory, School of Pharmacy & Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia.
² Department of Pharmacology, Toxicology & Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
³ Department of Pharmacy, University of Novi Sad, Novi Sad, Serbia.
⁴ The Group for Nano and Flexible Electronics, Faculty of Technical Sciences, University of Novi Sad, Novi Sad, Serbia.
⁵ Stem Cell & Cancer Biology Laboratory, School of Pharmacy & Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia.

PMID: 30444461
DOI: 10.4155/tde-2018-0036

Abstract

Aim: Deoxycholic acid (DCA) has improved gliclazide oral absorption, while Eudragit^® (ED) polymers have improved formulation stability of antidiabetic drugs. The aim of the study is to test if DCA and ED encapsulation will optimize the release and stability of the potential antidiabetic drug probucol (PB).

Materials & methods: The PB formulations were prepared using ED polymers and DCA, and formulations were analyzed for their rheological and biological properties.

Results: Rheological properties and size distribution were similar among all groups. β-cell survival and biological activities were best with NM30D microcapsules. The inflammatory profile and oxidative stress effects of microcapsules remained similar among all groups.

Conclusion: ED NM30D and DCA incorporation can exert positive and stabilizing effects on PB oral microcapsules.

Keywords: deoxycholic acid; microencapsulation; probucol.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Animals
Antioxidants / administration & dosage*
Antioxidants / pharmacokinetics
Biological Availability
Capsules
Cell Line
Cell Survival / drug effects
Deoxycholic Acid / chemistry
Drug Carriers / chemistry*
Drug Compounding / methods
Drug Evaluation, Preclinical
Drug Liberation
Hydrophobic and Hydrophilic Interactions
Hypoglycemic Agents / administration & dosage*
Hypoglycemic Agents / pharmacokinetics
Insulin-Secreting Cells / drug effects*
Insulin-Secreting Cells / metabolism
Mice
Oxidative Stress / drug effects
Polymethacrylic Acids / chemistry
Probucol / administration & dosage*
Probucol / pharmacology

Substances

Antioxidants
Capsules
Drug Carriers
Hypoglycemic Agents
Polymethacrylic Acids
Deoxycholic Acid
methylmethacrylate-methacrylic acid copolymer
Probucol